Antiangiogenesis Therapy of Endometriosis Using PAMAM as a Gene Vector in a Noninvasive Animal Model

Table 4

Area of fluorescent lesion in treatment and control groups at different time point (pixel).

Group	Day 5	Day 10	Day 15	Day 20	Day 25	Day 30
(1) HD PAMAM-Es^a	223104±60101	146451±54606	83812±52424	59549±49634	33301±36204	29676±36394
(2) LD PAMAM-Es^b	179970±64910	111880±59332	91058±73949	55692±46240	46290±39019	43015±41680
(3) Lipofectamine-ES^a,b	194664±62033	163435±56293	113506±50036	117513±62957	120533±71327	131120±71257
(4) PAMAM^a,b	200465±58021	154130±60652	128977±62570	138480±85150	160714±105618	161172±92100
(5) PBS^a,b	184576±57799	159941±78005	130626±50700	126370±58317	111729±44760	123874±62956

aStatistic significant difference between Group 1 and Group 3, Group 1 and Group 4, and Group 1 and Group 5 by Bonferroni test. ^bStatistic significant difference between Group 2 and Group 3, Group 2 and Group 4, and Group 2 and Group 5 by Bonferroni test. (Injecting one dose of various medicines into the endometrial lesion in each group mouse on day 10.)